What is Glyconics?
Glyconics is at the forefront of developing affordable, needle-free medical diagnostic solutions designed to deliver instant screening results. Their innovative technology aims to significantly enhance the efficiency and accessibility of medical testing for healthcare professionals and institutions. The company is dedicated to advancing the future of medical diagnostics through its cutting-edge product offerings.
How much funding has Glyconics raised?
Glyconics has raised a total of $2M across 1 funding round:
Other Financing Round
$2M
Other Financing Round (2021): $2M with participation from Deepbridge Capital, Wealth Club, and Boundary Capital Partners
Key Investors in Glyconics
Deepbridge Capital
Deepbridge Capital is a private investor network focused on innovative Life Sciences and Technology companies, catering to experienced investors and family offices seeking access to vetted EIS-qualifying companies.
Wealth Club
Wealth Club provides experienced investors with advanced investment opportunities beyond mainstream platforms, focusing on compelling and sophisticated financial instruments.
Boundary Capital Partners
Boundary Capital is an impact investment fund specializing in high-growth private technology companies, particularly in the AI sector, aiming for positive societal impact and offering tax-efficient investment opportunities.
What's next for Glyconics?
The recent major strategic investment positions Glyconics for accelerated growth and market penetration. This capital infusion is expected to fuel further research and development, expand operational capacity, and strengthen market outreach. The company's focus on enhancing diagnostic accessibility and efficiency suggests a strategic push towards broader adoption within the healthcare ecosystem, potentially leading to new partnerships and product line expansions.
See full Glyconics company page
